The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review [RETIRED]: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Open accessAbstract
In 1993, the last AAN Practice Parameter on medical treatment of Parkinson's disease (PD) concluded that levodopa was the most effective drug for management of this disorder. Since then, a number of new compounds including non-ergot dopamine agonists (DA) and sustained-release levodopa have been released and studied. Thus, the issue of treatment in de novo PD patients warrants reexamination. Specific questions include: 1) does selegiline offer neuroprotection; 2) what is the best agent with which to initiate symptomatic treatment in de novo PD; and 3) is there a benefit of sustained release levodopa over immediate-release levodopa? Using evidence-based principles, a literature review using MEDLINE, EMBASE, and the Cochrane Library was performed to identify all human trials in de novo PD between 1966 and 1999. Only articles that fulfilled class I or class II evidence were included. Based on this review, the authors conclude: 1) Selegiline has very mild symptomatic benefit (level A, class II evidence) with no evidence for neuroprotective benefit (level U, class II evidence). 2) For PD patients requiring initiation of symptomatic therapy, either levodopa or a DA can be used (level A, class I and class II evidence). Levodopa provides superior motor benefit but is associated with a higher risk of dyskinesia. 3) No evidence was found that initiating treatment with sustained-release levodopa provides an advantage over immediate-release levodopa (level B, class II evidence).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationEffects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
Bennett, D. A., Beckett, L. A., Murray, A. M., Shannon, K. M., Goetz, C. G., Pilgrim, D. M., & Evans, D. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601113340202 · Cited by 659
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Kostic, V., Przedborski, S., Flaster, E., & Sternic, N. (1991) · Neurology · doi:10.1212/wnl.41.2_part_1.202 · Cited by 297
Koller, W. C., Hutton, J. T., Tolosa, E., Capilldeo, R., & the Carbidopa/Levodopa Study Group (1999) · Neurology · doi:10.1212/wnl.53.5.1012 · Cited by 200
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390106 · Cited by 170
Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
Shoulson, & Parkinson Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410430309 · Cited by 165
On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
Nutt, J. G. (1987) · Annals of Neurology · doi:10.1002/ana.410220415 · Cited by 159
Selegiline delays the onset of disability in de novo parkinsonian patients
Pålhagen, S., Heinonen, E. H., Hägglund, J., Kaugesaar, T., Kontants, H., Mäki-Ikola, O., Palm, R., Turunen, J., & *Swedish Parkinson Study Group (1998) · Neurology · doi:10.1212/wnl.51.2.520 · Cited by 149
Cabergoline in the treatment of early parkinson's disease
Rinne, U. K., Bracco, F., Chouza, C., Dupont, E., Gershanik, O. S., Martí-Massó, J. F., Montastruc, J., MARSDEN, C. D., Dubini, A., Orlando, N., et al. (1997) · Neurology · doi:10.1212/wnl.48.2.363 · Cited by 130
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
Rinne, U. K. (1989) · Neurology · doi:10.1212/wnl.39.3.336 · Cited by 127
Horn, G. V., Schiess, M. C., & Koller, W. C. (2000) · Neurology · doi:10.1212/wnl.55.1.156 · Cited by 119
Deprenyl Protects Dopamine Neurons from the Neurotoxic Effect of 1‐Methyl‐4‐Phenylpyridinium Ion
Mytilineou, C., & Cohen, G. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb10556.x · Cited by 108
A case‐control study of multiple sclerosis
Operskalski, E. A., Visscher, B. R., Malmgren, R. M., & Detels, R. (1989) · Neurology · doi:10.1212/wnl.39.6.825 · Cited by 107
Costs of drug treatment in Parkinson's disease
Dodel, R. C., Eggert, K. M., Singer, M. S., Eichhorn, T. E., Pogarell, O. M., & Oertel, W. H. (1998) · Movement Disorders · doi:10.1002/mds.870130209 · Cited by 84
Scheife, R. T., Schumock, G. T., Burstein, A. H., Gottwald, M. D., & Luer, M. S. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.10.953 · Cited by 70
The initial treatment of Parkinson's disease should begin with levodopa
Weiner, W. J. (1999) · Movement Disorders · Cited by 58
Cerebrospinal Fluid Homovanillic Acid in the DATATOP Study on Parkinson's Disease
Parkinson Study Group (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540270025015 · Cited by 57
Cost-effectiveness analysis in Parkinson's disease: Determining the value of interventions
Siderowf, A. D., Holloway, R. G., & Stern, M. B. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<439::aid-mds1004>3.0.co;2-f · Cited by 37
A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky, J., López‐Villegas, D., García‐Sánchez, C., Barbanoj, M. J., Gironell, A., & Pascual‐Sedano, B. (1998) · PubMed · Cited by 35
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Takagi, Y., Takahashi, J. A., Saiki, H., Morizane, A., Hayashi, T., Kishi, Y., Fukuda, H., Okamoto, Y., Koyanagi, M., Ideguchi, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200521137 · Cited by 501
Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders
Enogieru, A. B., Haylett, W., Hiss, D. C., Bardien, S., & Ekpo, O. E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6241017 · Cited by 476
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Metadata
- Venue
- Neurology
- Published
- 2002-01-08
- Volume
- 58
- Issue
- 1
- Pages
- 11-17
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2155848097
- Cited by
- 373
- References
- 25
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.